SCHEMBL16060171

SCHEMBL16060171

O=[N+]([O-])c1ccc(OCc2ccccc2)c(Cl)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.50
CTSV O60911 3/20 0.47
CTSL P07711 3/20 0.47
POLB P06746 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 2/20 0.46
TTR P02766 1/20 0.44
ALB P02768 1/20 0.44
THRB P10828 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPK14 Q16539 1/20 0.44
PTGES O14684 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ATM Q13315 1/20 0.42
SGMS2 Q8NHU3 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31426422 0.89 PIN1 (0.50) PIN1CTSVCTSLPOLBMEN1
SCHEMBL573839 0.87 CTSV (0.49) PIN1CTSVCTSLPOLBMEN1
SCHEMBL573614 0.84 MAPT (0.53) PIN1CTSVCTSLPOLBMEN1
SCHEMBL8546360 0.83 PIN1 (0.50) PIN1CTSVCTSLPOLBMEN1
SCHEMBL30792251 0.83 MRGPRX4 (0.43) CTSVCTSLPOLBMEN1KMT2A
SCHEMBL2477351 0.82 CTSV (0.50) PIN1CTSVCTSLPOLBMEN1
SCHEMBL27096866 0.82 KMT2A (0.44) MEN1KMT2ATTRALBTHRB
SCHEMBL1937604 0.81 PIN1 (0.53) PIN1CTSVCTSLPOLBMEN1
SCHEMBL31234027 0.81 PIN1 (0.53) PIN1CTSVCTSLPOLBMEN1
SCHEMBL7110475 0.81 HTR1A (0.53) PIN1CTSVCTSLPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. 2025-07-31 US disclosed
EP-4392423-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE Arthrosi Therapeutics, Inc. (US) 2024-07-03 EP disclosed
WO-2023028054-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
US-20160046619-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2016-02-18 US disclosed
US-9133183-B2 Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-09-15 US disclosed
US-20140315917-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-10-23 US disclosed
WO-2014145015-A2 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046619-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R PIN1 4698/4885CTSV 619/4885CTSL 476/4885
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE EGFR, ABL1, ERBB2 PIN1 1720/4885CTSV 2384/4885CTSL 1822/4885
US-20140315917-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R PIN1 4698/4885CTSV 619/4885CTSL 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.